Roxadustat

Last updated

Roxadustat
Roxadustat.svg
Clinical data
Trade names Evrenzo
Other namesFG-4592, ASP1517, AZD9941
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
  • EU:Rx-only [1]
  • In general: ℞ (Prescription only)
Identifiers
  • 2-[(4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard 100.245.356 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C19H16N2O5
Molar mass 352.346 g·mol−1
3D model (JSmol)
  • CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O
  • InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
  • Key:YOZBGTLTNGAVFU-UHFFFAOYSA-N

Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD). [2] [3] It is taken by mouth. [1] The drug was developed by FibroGen, in partnership with AstraZeneca.

Contents

The most common side effects include hypertension (high blood pressure), vascular access thrombosis (formation of blood clots in the blood vessels associated with dialysis), diarrhea, peripheral edema (swelling especially of the ankles and feet), hyperkalemia (high blood potassium levels) and nausea (feeling sick). [1]

Roxadustat received its first global approval in China on 17 December 2018, [4] for the treatment of anemia caused by CKD in patients who are dialysis-dependent. [5] It was approved in Japan in 2019, for the treatment of anemia caused by CKD in patients on dialysis, and in 2020 for patients not on dialysis. [6] Roxadustat was approved for medical use in the European Union in August 2021. [1] [7]

Medical uses

Roxadustat is indicated for treatment of adults with symptomatic anemia associated with chronic kidney disease (CKD). [1]

Adverse effects

Roxadustat is reported to increase VEGF, a signal protein that can activate tumor growth [8] and also is considered to cause pulmonary hypertension. [9] In phase 3 trial conducted at 29 sites in China, roxadustat treatment was found to cause hyperkalemia, i.e., increase in serum potassium, and metabolic acidosis in patients. [10]

Society and culture

In July 2021, the Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted against the use of roxadustat in people with anemia in chronic kidney disease, both for those that are non-dialysis-dependent and those that are on dialysis. [11] Significant safety concerns were raised that the panelists believed could not be addressed without further study. [12] Notably, prior to the vote of the FDA committee, FibroGen and AstraZeneca announced that the company had changed parameters used to analyze cardiovascular safety data, which made the drug appear safer than it is. [13]

Usage as a doping product

Due to the potential applications of roxadustat in athletic doping, such as raising haemoglobin levels and stimulating the production of red blood cells, [14] it has been incorporated into screens for performance-enhancing drugs, as it has already been detected being used illicitly by athletes. [15] [16] [17] In March 2024, following a lengthly process, former world No. 1 tennis player Simona Halep received a nine month ban for unintentional use of roxadustat that was sourced to a contaminated supplement that she had ingested. [14] [18] [19]

References

  1. 1 2 3 4 5 "Evrenzo EPAR". European Medicines Agency (EMA). 23 June 2021. Retrieved 24 August 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ↑ Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, et al. (June 2016). "Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD". Clinical Journal of the American Society of Nephrology. 11 (6): 982–991. doi:10.2215/CJN.06890615. PMC   4891748 . PMID   27094610.
  3. ↑ Becker K, Saad M (April 2017). "A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat". Advances in Therapy. 34 (4): 848–853. doi: 10.1007/s12325-017-0508-9 . PMID   28290095.
  4. ↑ Dhillon S (April 2019). "Roxadustat: First Global Approval". Drugs. 79 (5): 563–572. doi: 10.1007/s40265-019-01077-1 . PMID   30805897. S2CID   71147333.
  5. ↑ Dhillon S (April 2019). "Roxadustat: First Global Approval". Drugs. 79 (5): 563–572. doi: 10.1007/s40265-019-01077-1 . PMID   30805897. S2CID   71147333.
  6. ↑ "Astellas Receives Approval of Evrenzo (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis". Astellas. 27 November 2020.
  7. ↑ "Evrenzo Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  8. ↑ Zhou M, Hou J, Li Y, Mou S, Wang Z, Horch RE, et al. (April 2019). "The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model". Scientific Reports. 9 (1): 6035. Bibcode:2019NatSR...9.6035Z. doi:10.1038/s41598-019-41924-5. PMC   6465281 . PMID   30988335.
  9. ↑ Cygulska K, Wejner-Mik P, Plewka M, Figiel Ł, Chrzanowski Ł, Kasprzak JD (May 2019). "Roxadustat: another drug that causes pulmonary hypertension? Report of first human case". Polish Archives of Internal Medicine. 129 (5): 344–345. doi: 10.20452/pamw.4445 . PMID   30758318.
  10. ↑ Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, et al. (September 2019). "Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis". The New England Journal of Medicine. 381 (11): 1001–1010. doi: 10.1056/NEJMoa1813599 . PMID   31340089.
  11. ↑ "FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease". FibroGen (Press release). Retrieved 15 July 2021.
  12. ↑ Sagonowsky E (15 July 2021). "AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety data". FiercePharma. Retrieved 16 July 2021.
  13. ↑ Liu A (7 April 2021). "FibroGen admits to messing with roxadustat safety data, upending hopes for the AZ-partnered anemia drug". Fierce Pharma. Retrieved 30 October 2022.
  14. 1 2 Ingle S (12 September 2023). "Simona Halep given four-year ban from tennis for anti-doping violations". The Guardian. Retrieved 12 September 2023.
  15. ↑ Beuck S, Schänzer W, Thevis M (November 2012). "Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis". Drug Testing and Analysis. 4 (11): 830–845. doi: 10.1002/dta.390 . PMID   22362605.
  16. ↑ Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A (March 2016). "Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case". Journal of Pharmaceutical and Biomedical Analysis. 121: 181–187. doi:10.1016/j.jpba.2016.01.029. PMID   26808067.
  17. ↑ Eichner D, Van Wagoner RM, Brenner M, Chou J, Leigh S, Wright LR, et al. (November 2017). "lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls". Drug Testing and Analysis. 9 (11–12): 1768–1778. doi: 10.1002/dta.2202 . PMID   28378453.
  18. ↑ MacInnes P (21 October 2022). "Simona Halep vows to 'fight for the truth' after positive doping test". The Guardian. Retrieved 21 October 2022.
  19. ↑ Carayol T (5 March 2024). "Simona Halep's 'triumph of truth' after doping ban significantly reduced". The Guardian. Retrieved 6 March 2024.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.